TransThera Sciences (Nanjing) Inc

Company Profile

• Business description

  TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its Core Product Tinengotinib is a unique multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.

• Contact

  Biotech and Pharmaceutical Valley
  3rd floor, Building 9, Accelerator Phase 2
  Jiangbei New Area
  Jiangsu Province
  Nanjing210032
  CHN

  T: +86 2558216200

  http://www.transthera.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  31 December 2025

  Employees

  121